GC Cell, Ulsan University Hospital forge strategic partnership in stem cell research

GC Cell said it has signed a memorandum of understanding (MOU) with Ulsan University Hospital for strategic cooperation in research and production of mesenchymal stem cells (MSC).

Under the accord, the two parties will facilitate the exchange of research findings and technologies. Ulsan University Hospital, designated as an advanced regenerative medicine institution by the Ministry of Health and Welfare, will share its clinical research results on advanced regenerative medicine. In turn, GC Cell will contribute its expertise in basic MSC research, clinical material production, and manufacturing techniques.

GC Cell anticipates that this cooperation could lead to participation in national research projects with Ulsan University Hospital's Biomedical Research Institute and potentially result in Contract Manufacturing Organization (CMO) agreements for clinical materials.

Ulsan University Hospital's Biomedical Research Institute comprises of several specialized centers, including the Biomedical Science Research Institute, Clinical Trial Center, Medical Device Innovation Center, Big Data Center, and Human-derived Material Bank. 

According to GC Cell, the institute plays a crucial role in elucidating disease mechanisms, developing therapeutic technologies, and conducting clinical trials. It also boasts advanced research facilities, including animal testing laboratories and LMO (living modified organism) research environments, as well as proprietary medical big data infrastructure such as uICE (research retrieval system) and clinical data warehouse (CDW).

GC Cell specializes in CDMO (contract development and manufacturing organization) services for cell therapies. 

The company offers a comprehensive solution for cell and gene therapy production, encompassing process and analytical method development, manufacturing of culture media and raw materials for advanced biopharmaceuticals, good manufacturing practice (GMP)-standard quality analysis services, production for clinical trials and commercialization, and long-term storage and logistics services for advanced biopharmaceuticals.